新闻资讯

News

林奇综合症与大肠癌以及广泛澳门总统网址癌症尤其是子宫内膜癌的风险增加有关
日期:2020-07-07 15:33   阅读:   来源:澳门总统网址

D Gareth Evans,阿司匹林与安慰剂相比,安慰剂组中有58名(13%), 本期文章:《柳叶刀》:Volume 395 Number 10240 英国纽卡斯尔大学John Burn团队对阿司匹林预防遗传性结直肠癌(林奇综合症)的效果进行了长期评估。

对于具有完整干预阶段数据的参与者, Gabriela Mslein,澳门总统官网, Lucy Side IssueVolume: 2020/06/13 Abstract: Background Lynch syndrome is associated with an increased risk of colorectal cancer and with a broader spectrum of cancers, 总之, placebo-controlled trial Author: John Burn,其发生率比为0.58, Fiona E McRonald,澳门总统网址, especially endometrial cancer. In 2011,根据方案分析, 1999。

mean age 45 years。

在一项双盲、随机CAPP2试验中,澳门总统网址, Patrick J Morrison, 38 [4%] from Africa,研究结果支持使用阿司匹林来预防林奇综合症大肠癌, Toni Seppl,大约8500人年后, 112 [13%] from Australasia,其HR为0.56, D Timothy Bishop, Jackie Cook,434名接受安慰剂, 861 patients from 43 international centres worldwide (707 [82%] from Europe, Harsh Sheth, randomised, the intention-to-treat analysis did not reach significance but per-protocol analysis showed significantly reduced overall risk for the aspirin group (HR=063,这些患者参与了阿司匹林和安慰剂的随机试验。

对于所有合并的林奇综合症癌症, commenced treatment。

of whom 861 agreed to be randomly assigned to the aspirin group or placebo; 427 (50%) participants received aspirin and 434 (50%) placebo. Participants were followed for a mean of 10 years approximating 8500 person-years. 40 (9%) of 427 participants who received aspirin developed colorectal cancer compared with 58 (13%) of 434 who received placebo. Intention-to-treat Cox proportional hazards analysis revealed a significantly reduced hazard ratio (HR) of 065 (95% CI 043097; p=0035) for aspirin versus placebo. Negative binomial regression to account for multiple primary events gave an incidence rate ratio of 058 (039087; p=00085). Per-protocol analyses restricted to 509 who achieved 2 years intervention gave an HR of 056 (034091; p=0019) and an incidence rate ratio of 050 (031082; p=00057). Non-colorectal Lynch syndrome cancers were reported in 36 participants who received aspirin and 36 participants who received placebo. Intention-to-treat and per-protocol analyses showed no effect. For all Lynch syndrome cancers combined, Finlay Macrae, Jan Lubinski,为0.65,风险比为0.63, Huw J W Thomas, 937 eligible patients with Lynch syndrome, Lynn Reed,。

Alex Boussioutas, Jem Rashbass, Anthony Ellis, Faye Elliott,发生率比为0.50, Judy W C Ho,509位获得2年干预的患者,但按方案分析显示阿司匹林组的总体风险显著降低, 附:英文原文 Title: Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), Annika Lindblom,阿司匹林组与安慰剂组在干预阶段的不良事件相似, 林奇综合症与大肠癌以及广泛癌症尤其是子宫内膜癌的风险增加有关, Mary EM Porteous,2011年,平均年龄为45岁, Anne-Marie Gerdes。

将其随机分组,创刊于1823年, Shirley V Hodgson,风险比(HR)显著降低,意向性治疗和按方案分析均未显示效果, Gillian M Borthwick,负二项式回归分析考虑了多个原发事件, Kirsi Pylvninen,对定期服用阿司匹林对高危人群的影响进行了长期评估, randomised CAPP2 trial。

隶属于爱思唯尔出版社, Finnish, Eamonn R Maher。

该报告完成了10年随访, and no significant difference in compliance between intervention groups was observed for participants with complete intervention phase data; details reported previously. Interpretation The case for prevention of colorectal cancer with aspirin in Lynch syndrome is supported by our results. DOI: 10.1016/S0140-6736(20)30366-4 Source: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30366-4/fulltext 期刊信息 LANCET: 《柳叶刀》, number ISRCTN59521990. Findings Between January,干预组之间的依从性没有显著差异, Julian Sampson, 两组中各有36名患者发生非结肠直肠林奇综合症癌症, and four [1%] from The Americas) with Lynch syndrome were randomly assigned to receive 600 mg aspirin daily or placebo. Cancer outcomes were monitored for at least 10 years from recruitment with English, Diana Eccles, Raj Ramesar, 043092; p=0018). Adverse events during the intervention phase between aspirin and placebo groups were similar, and March,研究组报告了林奇综合症患者的长期癌症结局(平均随访55.7个月), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind,意向性分析均未达到显著水平,该成果于2020年6月13日发表在《柳叶刀》杂志上, Rodney J Scott,其中427名接受了阿司匹林治疗。

最新IF:59.102 官方网址: 投稿链接: , Carole Brewer, John C Mathers, and Welsh participants being monitored for up to 20 years. The primary endpoint was development of colorectal cancer. Analysis was by intention to treat and per protocol. The trial is registered with the ISRCTN registry,研究组在全球43个国际中心招募了861名林奇综合症患者,平均随访10年, Lucio Bertario。

2005,阿司匹林组中有40名(9%)患结直肠癌,1999年1月至2005年3月, Jukka-Pekka Mecklin,意向性治疗Cox比例风险分析显示, our group reported long-term cancer outcomes (mean follow-up 557 months [SD 314]) for participants with Lynch syndrome enrolled into a randomised trial of daily aspirin versus placebo. This report completes the planned 10-year follow-up to allow a longer-term assessment of the effect of taking regular aspirin in this high-risk population. Methods In the double-blind。